These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.
Malaria has long been a global scourge, killing some 500,000 people a year, more than half of them children under 5. But that may be about to change, thanks to the introduction of a malaria vaccine—the first vaccine ever against a parasitic infection. The shot has been in the works since 1987, at a cost of more than $750 million, mostly funded by the Bill and Melinda Gates Foundation and GlaxoSmithKline. Dubbed Mosquirix, it was recommended for approval by the World Health Organization in October, after a field trial involving 800,000 children in Ghana, Kenya and Malawi. The four-dose regimen was found to cut the risk of infection by 40% and the risk of severe infection by 30%. —Jeffrey Kluger
More Must-Reads from TIME
- Why Trump’s Message Worked on Latino Men
- What Trump’s Win Could Mean for Housing
- The 100 Must-Read Books of 2024
- Sleep Doctors Share the 1 Tip That’s Changed Their Lives
- Column: Let’s Bring Back Romance
- What It’s Like to Have Long COVID As a Kid
- FX’s Say Nothing Is the Must-Watch Political Thriller of 2024
- Merle Bombardieri Is Helping People Make the Baby Decision
